FRS ≥ 20% | Univariate analysis | Multivariate analysis | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|---|
Predictor | OR | 95% CI | P-value | OR | 95% CI | P-value | OR | 95% CI | P-value |
PREVEND subjects (n = 312) | |||||||||
 AAA-1 positivity | 0.79 | 0.47–1.33 | 0.395 | 1.03 | 0.57–1.85 | 0.922 | – | – | – |
 AAA-1 continuous | 2.11 | 0.84–5.30 | 0.113 | – | – | – | 1.85 | 0.64–5.3 | 0.252 |
 ALP | 1.04 | 1.02–1.06 |  < 0.001 | 1.03 | 1.01–1.05 | 0.001 | 1.03 | 1.01–1.05 | 0.001 |
 FLI | 1.02 | 1.01–1.03 |  < 0.001 | 1.02 | 1.01–1.03 |  < 0.001 | 1.02 | 1.01–1.03 |  < 0.001 |
FLI ≥ 60 PREVEND subjects (n = 112) | |||||||||
 AAA-1 positivity | 2.44 | 1.07–5.60 | 0.032 | 1.70 | 0.69–4.21 | 0.235 | – | – | – |
 AAA-1 continuous | 7.80 | 0.96–63.19 | 0.051 | – | – | – | 3.90 | 0.41–37.8 | 0.235 |
 ALP | 1.03 | 1.0–1.05 | 0.022 | 1.02 | 0.99–1.05 | 0.117 | 1.02 | 0.99–1.05 | 0.135 |
 FLI | 1.06 | 1.02–1.1 | 0.001 | 1.05 | 1.01–1.09 | 0.004 | 1.05 | 1.01–1.09 | 0.003 |
FLI < 60 PREVEND subjects (n = 200) | |||||||||
 AAA-1 positivity | 1.21 | 0.56–2.68 | 0.591 | 0.72 | 0.31–1.67 | 0.442 | – | – | – |
 AAA-1 continuous | 2.12 | 0.7–6.4 | 0.185 | – | – | – | 1.60 | 0.46–5.5 | 0.455 |
 ALP | 1.05 | 1.02–1.08 |  < 0.001 | 1.04 | 1.02–1.07 | 0.001 | 1.04 | 1.02–1.07 | 0.001 |
 FLI | 1.02 | 1–1.04 | 0.028 | 1.01 | 0.99–1.03 | 0.229 | 1.01 | 0.98–1.03 | 0.306 |